Glibenclamide for the treatment of acute CNS injury
| العنوان: | Glibenclamide for the treatment of acute CNS injury |
|---|---|
| المؤلفون: | Nicholas Caffes, Cigdem Tosun, Volodymyr Gerzanich, J. Marc Simard, Jason K. Karimy, Adam Pampori, David B. Kurland |
| المصدر: | Pharmaceuticals Pharmaceuticals, Vol 6, Iss 10, Pp 1287-1303 (2013) |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | endocrine system, Traumatic brain injury, medicine.medical_treatment, Sur1-Trpm4 channel, lcsh:Medicine, lcsh:RS1-441, Pharmaceutical Science, Review, Pharmacology, cerebral ischemia, lcsh:Pharmacy and materia medica, Glibenclamide, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Drug Discovery, medicine, metastatic brain tumor, Stroke, Spinal cord injury, 030304 developmental biology, 0303 health sciences, business.industry, Neonatal encephalopathy, Insulin, traumatic brain injury, lcsh:R, medicine.disease, spinal cord injury, encephalopathy of prematurity, 3. Good health, glibenclamide, Anesthesia, Molecular Medicine, Sulfonylurea receptor, business, 030217 neurology & neurosurgery, medicine.drug |
| الوصف: | First introduced into clinical practice in 1969, glibenclamide (US adopted name, glyburide) is known best for its use in the treatment of diabetes mellitus type 2, where it is used to promote the release of insulin by blocking pancreatic KATP [sulfonylurea receptor 1 (Sur1)-Kir6.2] channels. During the last decade, glibenclamide has received renewed attention due to its pleiotropic protective effects in acute CNS injury. Acting via inhibition of the recently characterized Sur1-Trpm4 channel (formerly, the Sur1-regulated NCCa-ATP channel) and, in some cases, via brain KATP channels, glibenclamide has been shown to be beneficial in several clinically relevant rodent models of ischemic and hemorrhagic stroke, traumatic brain injury, spinal cord injury, neonatal encephalopathy of prematurity, and metastatic brain tumor. Glibenclamide acts on microvessels to reduce edema formation and secondary hemorrhage, it inhibits necrotic cell death, it exerts potent anti-inflammatory effects and it promotes neurogenesis—all via inhibition of Sur1. Two clinical trials, one in TBI and one in stroke, currently are underway. These recent findings, which implicate Sur1 in a number of acute pathological conditions involving the CNS, present new opportunities to use glibenclamide, a well-known, safe pharmaceutical agent, for medical conditions that heretofore had few or no treatment options. |
| تدمد: | 1424-8247 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66067286d274ca703ba2e04fb3d66004 https://pubmed.ncbi.nlm.nih.gov/24275850 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....66067286d274ca703ba2e04fb3d66004 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14248247 |
|---|